<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957940</url>
  </required_header>
  <id_info>
    <org_study_id>17300631</org_study_id>
    <nct_id>NCT04957940</nct_id>
  </id_info>
  <brief_title>Lipid Emulsion Infusion and COVID-19 Patients</brief_title>
  <official_title>Fish-Oil-Based Lipid Emulsion Infusion (FOBLE): Could Early Use Provide a Potential Therapy to Stop Moderate Cases of COVID-19 Diseased Patient's Shift to ICU?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators suggest that early administration of intravenous lipid emulsion (ILE) affect&#xD;
      the inflammatory response and improve outcome in COVID-19. The aim of this trial is to study&#xD;
      the effect of fish-oil-based intravenous lipid emulsion (FOBLE) supplementation added to&#xD;
      enteral nutrition on shift to ICU for upgrading oxygenation &amp;/or ventilation in moderate&#xD;
      cases of Covid-19 diseased patients requiring only supplemental oxygen in form of simple&#xD;
      nasal cannula or venturi mask oxygen (during 7 days admission).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A written informed consent will be taken from the patients or their relatives. Patients will&#xD;
      be randomly assigned to receive standard enteral nutrition plus 100 ml/day 0.9% normal saline&#xD;
      at a rate 12.5 ml/h over 8 h for 5 days as the control group (Group C) or intravenous&#xD;
      fish-oil-based lipid (SMOF lipid 20% which contains a unique 4-oil mix containing Soya bean,&#xD;
      Medium-chain triglycerides, Olive oil and Fish oil) (Fresenius Kabi, Bad Homburg, Germany)&#xD;
      emulsion supplementation to standard enteral nutrition (group L) in a dose of 100 ml/day at a&#xD;
      rate of 12.5 ml/h over 8 h daily for 5 days.Finally, 20 mL of 0.9% normal saline was injected&#xD;
      into the burette to flush the system. The entire apparatus was disposed of when each infusion&#xD;
      was completed. The whole process was repeated for each infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2021</start_date>
  <completion_date type="Actual">September 26, 2021</completion_date>
  <primary_completion_date type="Actual">September 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shift of patients to ICU</measure>
    <time_frame>7 days</time_frame>
    <description>Patients will be shifted to ICU for upgrading oxygenation &amp;/or ventilation due to failed management in the intermediate care attached to our ICU (simple nasal cannula or venturi mask oxygen).According to the Chinese diagnosis and treatment guideline for COVID-19 (trial version 7.0), severe cases were defined as including one of the following criteria: (1) respiratory frequency &gt;30/min, (2) oxygen saturation ≤93%, and (3) PO2/FiO2 ≤300 (taking consideration that severe ARDS PO2/FiO2 ratio &lt; 100). Severe patients who need higher levels of oxygen support (high-flow nasal cannula HFNC or non invasive continuous positive airway pressure CPAP) to correct hypoxemia, or multiple organ dysfunction, are admitted to the ICU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of short-term outcome</measure>
    <time_frame>7 days</time_frame>
    <description>Assessing the percentage % of short-term outcome for cases admitted in the intermediate care attached to our ICU and numbers of patients either died, shifted to ICU for upgrading oxygenation and or ventilation or discharged to home.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>SMOF lipid 20% IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous fish-oil-based lipid (SMOF lipid 20%) emulsion supplementation to standard enteral nutrition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo IV infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous 0.9% saline supplementation to standard enteral nutrition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMOFlipid</intervention_name>
    <description>Intravenous fish-oil-based lipid (SMOF lipid 20%) (Fresenius Kabi, Bad Homburg, Germany) emulsion supplementation to standard enteral nutrition in a dose of 100 ml/day at a rate of 12.5 ml/h over 8 h daily for 5 days.</description>
    <arm_group_label>SMOF lipid 20% IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>0.9% saline</intervention_name>
    <description>Receive standard enteral nutrition plus 100 ml/day 0.9% normal saline at a rate 12.5 ml/h over 8 h for 5 days</description>
    <arm_group_label>Saline placebo IV infusion</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are with diagnosis of moderate cases of covid-19 (a person who may have lower&#xD;
             respiratory illness, such as pneumonia. However, their blood oxygen levels remain&#xD;
             ≥94%)&#xD;
&#xD;
          -  Requiring only supplemental oxygen in form of simple nasal cannula or venturi mask&#xD;
             oxygen admitted in the intermediate care attached to our ICU with good enteral&#xD;
             nutrition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity (peanut,eggs and soya bean)&#xD;
&#xD;
          -  Uncontrolled hyperlipidemia&#xD;
&#xD;
          -  Severe primary blood coagulation diseases&#xD;
&#xD;
          -  Acute pancreatitis&#xD;
&#xD;
          -  Acute thromboembolic diseases&#xD;
&#xD;
          -  Liver failure (bilirubin &gt;40 mmol/l, alanine aminotransferase &gt;100 U/l and aspartate&#xD;
             aminotransferase &gt;100 U/l)&#xD;
&#xD;
          -  RIFLE (Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease)&#xD;
             stage III and IV renal failure&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Severe neutropenia (&lt;500 cells/mm3)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar Soliman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <state>Assuit</state>
        <zip>Assuit universi</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002 Dec;21(6):495-505. Review.</citation>
    <PMID>12480795</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Omar Makram Soliman</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SMOFlipid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

